Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson's Disease

We report that rapamycin, an allosteric inhibitor of certain but not all actions of the key cellular kinase mammalian target of rapamycin (mTOR), protects neurons from death in both cellular and animal toxin models of Parkinson's disease (PD). This protective action appears to be attributable to blocked translation of RTP801/REDD1/Ddit4, a protein that is induced in cell and animal models of PD and in affected neurons of PD patients and that causes neuron death by leading to dephosphorylation of the survival kinase Akt. In support of this mechanism, in PD models, rapamycin spares phosphorylation of Akt at a site critical for maintenance of its survival-promoting activity. The capacity of rapamycin to provide neuroprotection in PD models appears to arise from its selective suppression of some but not all actions of mTOR, as indicated by the contrasting finding that Torin1, a full catalytic mTOR inhibitor, is not protective and induces Akt dephosphorylation and neuron death.

[1]  A. Marette,et al.  Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. , 2005, Endocrinology.

[2]  P. Bain.  CHANGING CONCEPTS IN PARKINSON DISEASE: MOVING BEYOND THE DECADE OF THE BRAIN , 2009, Neurology.

[3]  Wolfgang Arnold,et al.  REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase , 2005, Oncogene.

[4]  S. Kish,et al.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.

[5]  Wenhua Zheng,et al.  FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling , 2002, Journal of neurochemistry.

[6]  T. Hunter,et al.  Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies , 2004, Current Biology.

[7]  E. Hafen,et al.  Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. , 2004, Genes & development.

[8]  Jiang-Ning Zhou,et al.  Roles of autophagy and mTOR signaling in neuronal differentiation of mouse neuroblastoma cells. , 2008, Cellular signalling.

[9]  L. Greene,et al.  Death in the Balance: Alternative Participation of the Caspase-2 and -9 Pathways in Neuronal Death Induced by Nerve Growth Factor Deprivation , 2001, The Journal of Neuroscience.

[10]  J. Olefsky,et al.  A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. , 2000, Molecular endocrinology.

[11]  F. Zhong,et al.  Dexamethasone-induced Gene 2 (dig2) Is a Novel Pro-survival Stress Gene Induced Rapidly by Diverse Apoptotic Signals* , 2003, Journal of Biological Chemistry.

[12]  O. Isacson,et al.  Immunophilin Ligands and GDNF Enhance Neurite Branching or Elongation from Developing Dopamine Neurons in Culture , 2000, Experimental Neurology.

[13]  K. Pong,et al.  Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. , 2003, Current drug targets. CNS and neurological disorders.

[14]  David Park,et al.  Abberant α-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy , 2009, PloS one.

[15]  R. Abraham,et al.  Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells (*) , 1995, The Journal of Biological Chemistry.

[16]  David R. Kaplan,et al.  Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt , 1997, Science.

[17]  L. Swiech,et al.  Role of mTOR in physiology and pathology of the nervous system. , 2008, Biochimica et biophysica acta.

[18]  L. Helman,et al.  Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism , 2007, Oncogene.

[19]  Dena Leshkowitz,et al.  Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801, Involved in Apoptosis , 2002, Molecular and Cellular Biology.

[20]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[21]  Wei Zhang,et al.  Pharmacological Inhibition of mTORC1 Suppresses Anatomical, Cellular, and Behavioral Abnormalities in Neural-Specific Pten Knock-Out Mice , 2009, The Journal of Neuroscience.

[22]  R. Burke,et al.  Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease , 2006, Proceedings of the National Academy of Sciences.

[23]  Lloyd A Greene,et al.  Endoplasmic Reticulum Stress and the Unfolded Protein Response in Cellular Models of Parkinson's Disease , 2002, The Journal of Neuroscience.

[24]  Simon C Watkins,et al.  Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. , 2007, The American journal of pathology.

[25]  S. Korsmeyer,et al.  Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Snyder,et al.  Neural actions of immunophilin ligands. , 1998, Trends in pharmacological sciences.

[27]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[28]  Satoshi Orimo,et al.  Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease , 2008 .

[29]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[30]  J. Heitman,et al.  TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin (*) , 1995, The Journal of Biological Chemistry.

[31]  C. Thompson,et al.  Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. , 2003, Cancer research.

[32]  Karen Lipkow,et al.  Amelioration of protein misfolding disease by rapamycin: Translation or autophagy? , 2008, Autophagy.

[33]  C. Achim,et al.  Immunophilins and their ligands: insights into survival and growth of human neurons , 2002, Physiology and Behavior.

[34]  P. Crino,et al.  Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons , 2007, Epilepsy Research.

[35]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[36]  C. Johannessen,et al.  Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1 , 2005, Molecular and Cellular Biology.

[37]  Francesco Scaravilli,et al.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease , 2004, Nature Genetics.

[38]  D. Rubinsztein,et al.  Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies , 2009, Cell Death and Differentiation.

[39]  References , 1971 .

[40]  A. Nairn,et al.  Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Kakita,et al.  Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. , 2008, Brain : a journal of neurology.

[42]  L. Greene,et al.  Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps , 2009, Apoptosis.

[43]  J. Blenis,et al.  Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy , 2009, Cell cycle.

[44]  Sang Gyun Kim,et al.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.

[45]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[46]  Geoffrey M Cooper,et al.  Role of mTOR in the degradation of IRS‐1: Regulation of PP2A activity , 2002, Journal of cellular biochemistry.

[47]  D. Sgroi,et al.  Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. , 2008, Genes & development.

[48]  S. Kimball,et al.  Rapid Turnover of the mTOR Complex 1 (mTORC1) Repressor REDD1 and Activation of mTORC1 Signaling following Inhibition of Protein Synthesis* , 2008, Journal of Biological Chemistry.

[49]  J. Qin,et al.  SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity , 2006, Cell.

[50]  S. Snyder,et al.  RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Y. Agid,et al.  Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.

[52]  A. Yang,et al.  REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. , 2002, Molecular cell.

[53]  G. Crabtree,et al.  Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases , 1992, Cell.

[54]  Lloyd A Greene,et al.  RTP801 Is Elevated in Parkinson Brain Substantia Nigral Neurons and Mediates Death in Cellular Models of Parkinson's Disease by a Mechanism Involving Mammalian Target of Rapamycin Inactivation , 2006, The Journal of Neuroscience.

[55]  L. Greene,et al.  Analysis of gene expression changes in a cellular model of Parkinson disease , 2005, Neurobiology of Disease.

[56]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[57]  L. Greene,et al.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Blenis,et al.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression , 2004, Oncogene.

[59]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[60]  David R. Kaplan,et al.  Direct Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate , 1997, Science.

[61]  L. Greene,et al.  PC12 Cells as a model for parkinson's disease research , 2008 .

[62]  D. Rubinsztein,et al.  Rapamycin pre-treatment protects against apoptosis. , 2006, Human molecular genetics.

[63]  J. Avruch,et al.  Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. , 1992, Science.

[64]  Robert T. Abraham,et al.  Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 Is Mediated by p70S6 Kinase* , 2005, Journal of Biological Chemistry.

[65]  P. Castaigne,et al.  [Medical treatment of Parkinson's disease]. , 1972, Annales de medecine interne.

[66]  L. Greene,et al.  RTP801 Is Induced in Parkinson's Disease and Mediates Neuron Death by Inhibiting Akt Phosphorylation/Activation , 2008, The Journal of Neuroscience.

[67]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[68]  B. Manning,et al.  A complex interplay between Akt, TSC2 and the two mTOR complexes. , 2009, Biochemical Society transactions.

[69]  D. Rubinsztein,et al.  Small molecule enhancers of autophagy for neurodegenerative diseases. , 2008, Molecular bioSystems.